Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer  by Kim, Sun-Jin et al.
Macitentan (ACT-064992),
a Tissue-Targeting Endothelin
Receptor Antagonist, Enhances
Therapeutic Efficacy of
Paclitaxel by Modulating
Survival Pathways in Orthotopic
Models of Metastatic Human
Ovarian Cancer1,2
Sun-Jin Kim*,3, Jang Seong Kim*,3,
Seung Wook Kim*,3, Emily Brantley*,
Seok Joong Yun*, Junqin He*, Marva Maya*,
Fahao Zhang*, Qiuyu Wu*, François Lehembre†,
Urs Regenass† and Isaiah J. Fidler*
*Department of Cancer Biology, Cancer Metastasis
Research Center, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA; †Actelion
Pharmaceuticals, Ltd, Allschwil, Switzerland
Abstract
Potential treatments for ovarian cancers that have become resistant to standard chemotherapies include modula-
tors of tumor cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy
of the dual ETR antagonist, macitentan, on human ovarian cancer cells, SKOV3ip1 and IGROV1, growing ortho-
topically in nude mice. Mice with established disease were treated with vehicle (control), paclitaxel (weekly, intra-
peritoneal injections), macitentan (daily oral administrations), or a combination of paclitaxel and macitentan.
Treatment with paclitaxel decreased tumor weight and volume of ascites. Combination therapy with macitentan
and paclitaxel reduced tumor incidence and further reduced tumor weight and volume of ascites when compared
with paclitaxel alone. Macitentan alone occasionally reduced tumor weight but alone had no effect on tumor in-
cidence or ascites. Immunohistochemical analyses revealed that treatment with macitentan and macitentan plus
paclitaxel inhibited the phosphorylation of ETRs and suppressed the survival pathways of tumor cells by de-
creasing the levels of pVEGFR2, pAkt, and pMAPK. The dose of macitentan necessary for inhibition of phosphor-
ylation correlated with the dose required to increase antitumor efficacy of paclitaxel. Treatment with macitentan
enhanced the cytotoxicity mediated by paclitaxel as measured by the degree of apoptosis in tumor cells and
tumor-associated endothelial cells. Collectively, these results show that administration of macitentan in combina-
tion with paclitaxel prevents the progression of ovarian cancer in the peritoneal cavity of nude mice in part by
inhibiting survival pathways of both tumor cells and tumor-associated endothelial cells.
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Introduction
In 2009, ovarian cancer was the leading cause of death from gyneco-
logic cancer in the United States [1]. Despite initial response rates
that can exceed 80% [2,3], most patients with advanced ovarian can-
cer ultimately relapse with drug-resistant disease [4,5]. Because the
response rate to second-line agents is approximately 15% to 20%
[6], new therapeutic regimens are urgently needed for this devastat-
ing cancer. Recent approaches to overcoming tumor resistance to
chemotherapy include modulation of cell signaling pathways in-
volved in tumor cell growth and survival and of the interaction of
tumor cells with the organ microenvironment [7,8].
Abbreviations: ET, endothelin; ETR, endothelin receptor; ETAR, endothelin A recep-
tor; ETBR, endothelin B receptor; PBS, phosphate-buffered saline; VEGFR, vascular
endothelial growth factor receptor
Address all correspondence to: Isaiah J. Fidler, DVM, PhD, Department of Cancer Biol-
ogy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit
854, Houston, TX. E-mail: ifidler@mdanderson.org
1This work was supported in part by Cancer Center Support Core grant CA16672
and grant 1U54CA143837-01 from the National Cancer Institute, National Institutes
of Health, and by Actelion Pharmaceuticals, Ltd.
2This article refers to supplementary materials, which are designated by Figures W1 to
W3 and are available online at www.neoplasia.com.
3Equal first authorship.
Received 8 June 2010; Revised 18 October 2010; Accepted 22 October 2010
Copyright © 2011 Neoplasia Press, Inc. All rights reserved 1522-8002/11/$25.00
DOI 10.1593/neo.10806
www.neoplasia.com
Volume 13 Number 2 February 2011 pp. 167–179 167
One intriguing therapeutic possibility is based on antagonists of
the endothelin (ET) family of small peptides consisting of ET-1,
-2, and -3 [9,10]. ETs share structural homology and initiate signal-
ing by binding to G protein–coupled receptors ETAR and ETBR
[11–14]. ETs, initially defined as potent vasoconstrictors and non-
peptidic small molecule ETreceptor (ETR) antagonists [14,15], were
developed to treat cardiovascular diseases. For example, the dual
ETAR and ETBR inhibitor, bosentan, is now used to treat pulmonary
arterial hypertension [15–17].
It is important to note that ETs, beyond inducing vasoconstric-
tion, act as paracrine or autocrine tissue factors to regulate biologic
processes such as tissue remodeling and repair [18], smooth muscle
cell proliferation [19], and inflammation [20]. ETs and their re-
ceptors are expressed in many tumor types [21] and are involved
in tumor cell proliferation, migration, invasiveness, and vascular
differentiation [21–25]. In addition, activated ETRs have also been
reported to be involved in inhibition of apoptosis, matrix remodel-
ing, and bone deposition [10,11,13,14,16,21,26], in prostate can-
cer [27,28], lung cancer [29,30], colon cancer [31,32], renal
cancer [33], cervical cancer [34,35], brain tumors [36–38], ovarian
cancer [25,39–48], and other tumors [49,50]. ET production has
been demonstrated in many human tumor cell lines and human tu-
mors. In the tumor vasculature, the endothelium is the main source
of ET [49–51]. In most carcinoma cells, the dominating receptor is
the ETAR receptor [50], whereas in melanoma cells and glioblastoma
cells, the ETBR receptor is highly expressed [50,52]. Vascular endo-
thelial cells express high levels of ETBR receptors [53], and ETBR
receptor signaling has been associated with endothelial cell prolif-
eration, migration, differentiation, and vascular endothelial growth
factor (VEGF) induction [43,54–57].
The ET axis in ovarian cancer has been broadly studied [25,44–
46,58]. Examination of clinical specimens revealed increased expression
of ET-1 and ETAR in ovarian cancer cells, indicating their involvement
in an autocrine loop [44]. In another study using primary and meta-
static ovarian carcinomas, ETAR receptors were localized to carcinoma
cells and intratumoral vessels, whereas ETBR were mainly found in
the endothelial cells. VEGF production from cancer cells was found
to be stimulated by ET in vitro through induction of hypoxia-inducible
factor-1α [59], leading to VEGF-mediated neovascularization in vivo
[44,54,56]. The level of ET-1 is also increased in peritoneal ascitic
fluid of patients with ovarian carcinoma, suggesting a correlation with
the level of VEGF, whereas effusions from patients without cytologic
disease had low or undetectable levels of ET-1 [43]. Collectively, these
data indicate that the expression of ET-1 and ETAR correlates with
advanced stages of the disease [24,58,60].
In the present study, we determined whether the daily oral ad-
ministration of the dual ETR receptor antagonist macitentan [61],
combined with once-weekly intraperitoneal injections of paclitaxel,
produced significant therapeutic effects in intraperitoneally trans-
planted human ovarian tumor xenografts in nude mice. Therapeutic
effects were correlated with induction of apoptosis in both tumor cells
and tumor-associated endothelial cells and the inhibition of phosphor-
ylation of proteins involved in signal transduction and cell survival.
Materials and Methods
Human Ovarian Cancer Cell Lines
Highly metastatic human ovarian cancer cell lines, SKOV3ip1 [61]
and IGROV1 [62, 63], were maintained as monolayer cultures in Eagle
minimal essential medium supplemented with 10% fetal bovine serum
(Life Technologies, Inc, Grand Island, NY), L-glutamine, pyruvate, non-
essential amino acids, two-fold vitamins, and penicillin-streptomycin
(Invitrogen, Carlsbad, CA) and incubated at 37°C in 5% CO2 and
95% air. Immorto mouse lung endothelial cells were incubated at
33°C [64]. All reagents used for tissue culture were free of endotoxin,
Mycoplasma, and viral pathogens, reovirus type 3; pneumonia virus;
K virus; Theiler’s encephalitis virus; Sendai virus; min virus; mouse
adenovirus; mouse hepatitis virus; lymphocytic choriomeningitis virus;
ectromelia virus; and lactate dehydrogenase virus (assayed by M. A.
Bioproducts, Walkersville, MD).
Reagents
Macitentan, also called ACT-064992 or (N -[5-(4-bromophenyl)-
6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl]-N ′-propyl-
aminosulfonamide), was provided by Actelion Pharmaceuticals, Ltd
(Allschwil, Switzerland) as powder. For oral administration, macitentan
was reconstituted in 0.05% (wt/wt) methylcellulose solution con-
taining 0.05% (vol/vol) Tween 80 and diluted to different concentra-
tions in 200 μl of vehicle before use. Paclitaxel (Taxol), purchased from
Bristol-Myers Squibb (Princeton, NJ), was diluted in distilled water
for intraperitoneal injection.
Animals
Female athymic nude mice (NCI-nu) were purchased from the
Animal Production Area of the National Cancer Institute – Frederick
Cancer Research Facility (Frederick, MD). The mice were housed
and maintained in specific pathogen-free conditions in facilities ap-
proved by the American Association for Accreditation of Laboratory
Animal Care and in accordance with all current regulations and stan-
dards of the US Department of Agriculture, the US Department of
Health and Human Services, and the National Institutes of Health.
The mice were used in these experiments in accordance with institu-
tional guidelines when they were 8 to 12 weeks old.
Orthotopic Implantation of Ovarian Cancer in Animal Models
To produce tumors, SKOV3ip1 and IGROV1 cells were harvested
from subconfluent cultures by a brief exposure to 0.25% trypsin and
0.02% EDTA. Trypsinization was stopped by replacing the trypsin-
EDTA with medium containing 10% fetal bovine serum, and the
cells were washed once in serum-free medium and resuspended in
Ca2+-/Mg2+-free Hank’s balanced salt solution. Cell viability was de-
termined by trypan blue exclusion, and only single-cell suspensions
of more than 95% viability were used for injection. In a preliminary
experiment, 1 × 106 cells in 200 μl of Ca2+-/Mg2+-free Hank’s bal-
anced salt solution were injected into the peritoneal cavity of female
nude mice. Ten days after the injection, three mice were randomly
selected and examined by necropsy to confirm development of tu-
mors (Figure W1).
Therapy Experiments
To induce peritoneal tumors, SKOV3ip1 (1 × 106) or IGROV1
(1 × 106) cells were injected into the peritoneal cavity of female nude
mice. Ten days later, the mice were randomized into treatment groups
(n = 10). In the first set of experiments, we investigated the therapeutic
effect of macitentan. Mice were implanted with SKOV3ip1 and ran-
domized into the following treatment groups: 1) daily oral adminis-
tration and weekly intraperitoneal injection of vehicle (control), 2)
weekly intraperitoneal injections of paclitaxel (5 mg/kg) and daily oral
168 Blockade of ETR for Therapy of Ovarian Cancer Kim et al. Neoplasia Vol. 13, No. 2, 2011
administration of vehicle, 3) daily oral administration of macitentan
(100 mg/kg) and weekly intraperitoneal injection of vehicle, and 4)
daily oral administration of macitentan (100 mg/kg) and weekly intra-
peritoneal injection of paclitaxel (5 mg/kg). These treatments were
continued for 4 weeks.
In this first set of experiments, the therapeutic effect of macitentan
was confirmed, but serious toxicities, such as weight loss, poor skin
turgor, dehydration, diarrhea, and sluggishness, were observed.
Therefore, in the second set of experiments, we determined the bio-
logic optimal dose of macitentan. Ten days after the intraperitoneal
implantation of SKOV3ip1 (1 × 106), mice were randomized into
five groups (n = 10): 1) daily oral administration and weekly intra-
peritoneal injection of vehicle (control), 2) weekly intraperitoneal
injection of paclitaxel (5 mg/kg) and daily oral administration of
vehicle, 3) weekly intraperitoneal injection of paclitaxel (5 mg/kg)
and daily oral administration of macitentan (30 mg/kg), 4) weekly
intraperitoneal injection of paclitaxel (5 mg/kg) and daily oral admin-
istration of macitentan (10 mg/kg), and 5) weekly intraperitoneal
injection of paclitaxel (5 mg/kg) and daily oral administration of
macitentan (3 mg/kg).
In the third set of experiments, we determined whether blockade
of the ET axis with the ET antagonist macitentan could increase the
sensitivity of cancer cells to lower doses of paclitaxel. Ten days after
the intraperitoneal implantation of SKOV3ip1 (1 × 106), mice were
randomized into six groups (n = 10): 1) daily oral administration and
weekly intraperitoneal injections of vehicle (control), 2) weekly intra-
peritoneal injections of nontherapeutic dose of paclitaxel (2 mg/kg)
and daily oral administration of vehicle, 3) weekly intraperitoneal in-
jections of therapeutic dose of paclitaxel (5 mg/kg) and daily oral ad-
ministration of vehicle, 4) daily oral administration of macitentan
(50 mg/kg) and weekly intraperitoneal injections of vehicle, 5) daily
oral administration of macitentan (50 mg/kg) and weekly intraperi-
toneal injections of nontherapeutic dose of paclitaxel (2 mg/kg), and
6) daily oral administration of macitentan (50 mg/kg) and weekly
intraperitoneal injections of therapeutic dose of paclitaxel (5 mg/kg).
These treatments were continued for 4 weeks.
From these three sets of experiments, we concluded that 50 mg/kg of
macitentan is a biologically optimal dose, and so further therapy experi-
ments were repeated with the 50-mg/kg dose. To determine whether
therapeutic effects were not limited to SKOV3ip1, we did experiments
using an additional human ovarian cancer cell line, IGROV1.
Necropsy Procedures and Preparation of Tissues
After 4 weeks of treatment, mice were injected in the tail vein with
100 μl of BrdU (Sigma; 25 mg/ml). Two hours later, the mice were
killed by intramuscular injection of Nembutal (1 g/kg) and examined
by necropsy. Tumor incidence, tumor weight, and volume of ascites
were recorded (Figure W2). Tumor tissues were embedded in OCT
compound (Miles, Inc, Elkhart, IN) and rapidly frozen in liquid ni-
trogen or fixed in 10% buffered formalin for 24 hours and processed
for paraffin block.
Immunohistochemical Analyses and TUNEL Assay
Primary antibodies used in this study were: mouse anti-BrdU
monoclonal antibody (1:400; Becton Dickinson, San Jose, CA), rat
antimouse CD31 monoclonal antibody (1:600; BD Pharmingen,
San Diego, CA), goat antihuman ET-1 polyclonal antibody (1:200;
Santa Cruz Biotechnology, Inc, Santa Cruz, CA), goat antihuman
ET-2 polyclonal antibody (1:200; Santa Cruz Biotechnology, Inc),
goat antihuman ETAR polyclonal antibody (1:200, immunohisto-
chemistry experiments; Santa Cruz Biotechnology, Inc), rabbit anti-
ETAR (1:200, immunohistochemistry experiments; Acris, Herford,
Germany), goat antihuman ETBR polyclonal antibody (1:200, immu-
nofluorescence experiments; Santa Cruz Biotechnology, Inc), rabbit
anti-ETBR (1:200, immunohistochemistry experiments; Acris), rabbit
antimouse phosphorylated Akt monoclonal antibody (1:200; Cell Sig-
naling Technology, Boston, MA), rabbit antihuman phosphorylated-
p44/42 MAP kinase (Thr202/Tyr204) polyclonal antibody (1:200;
Cell Signaling Technology), and rabbit antihuman phosphorylated
VEGF receptor 2 (VEGFR2) monoclonal antibody (1:200; Cell Signal-
ing Technology). HRP-conjugated donkey antigoat IgG (1:400; Santa
Cruz Biotechnology), goat antirat Alexa 594 IgG (1:400; Invitrogen),
rabbit antigoat Alexa 488 IgG (1:400; Invitrogen), rabbit antigoat
FITC IgG (1:400; Jackson Immunoresearch Laboratories, West Grove,
PA), and goat antirabbit Alexa 488 IgG (1:400; Invitrogen) were pur-
chased for use as secondary antibodies. TUNEL assay was performed
using a commercial apoptosis detection kit (Promega Corp, Madison,
WI) with modification [9]. For color reaction of HRP-conjugated sec-
ondary antibodies, stable 3′,3-diaminobenzidine (Research Genetics,
Huntsville, AL) was used.
Immunofluorescence Staining
To determine the expression of ET-1, ET-2, ETAR, ETBR, phos-
phorylated VEGFR2 (pVEGFR2), phosphorylated Akt (pAkt), and
phosphorylated MAP kinase (pMAPK) on tumor cells and/or tumor-
associated endothelial cells, tissues were costained with anti-CD31
antibody and anti–ET-1, anti–ET-2, anti-ETAR, anti-ETBR, anti-
pVEGFR2, or anti-pAkt antibodies. In brief, frozen slides were air-
dried and fixed in acetone. After washing with phosphate-buffered
saline (PBS), blocking for nonspecific protein was done with 4% fish
gel. The slides were incubated with primary antibodies for 18 hours,
washed with PBS three times, and incubated with compatible sec-
ondary antibodies for 2 hours at room temperature. During incuba-
tion, the slides were shielded from ambient light. For examination of
the endothelium, colocalization staining with CD31 was performed
followed by staining with the second primary antibodies as described
previously [8].
Proliferative and apoptotic indices of tumor-associated endothelial
cells as well as tumor cells were determined by colocalization of CD31
and anti-BrdU or TUNEL staining. Images were captured by an Olym-
pus BX-51 microscope (Olympus America, Inc, Center Valley, PA).
Double Immunofluorescence Staining for ETRs
and Phospho-Serine in Tumor Tissues
Because specific antibodies to detect activated, serine/threonine–
phosphorylated ETRs were not available, we used double immunoflu-
orescence staining with anti-ETAR or ETBR and anti–phospho-serine
antibodies. Tissue sections (6-8 μm) of frozen samples were mounted
on positively charged slides and air-dried for 30 minutes. The sections
were fixed in cold acetone for 10 minutes, washed three times with
PBS for 3 minutes, and incubated with protein blocking solution con-
taining 5% normal horse serum and 1% normal goat serum in PBS for
20 minutes at room temperature. The slides were incubated with a pri-
mary antibody against ETAR (1:100, 12977; Abcam, Cambridge, MA)
or ETBR (1:100, 65972; Abcam) at 4°C overnight, washed three times
with PBS, and then incubated with AlexaFluor 594 goat anti–rabbit
secondary antibody (1:600 dilution, A11037; Invitrogen). The slides
were then incubated with the blocking solution at room temperature
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for 30 minutes and then incubated at 4°C overnight with primary
antibody against phospho-serine (1:100, sc-81514; Santa Cruz Bio-
technology). The slides were then washed three times with PBS for
3 minutes and incubated at room temperature for 1 hour with Alexa
Fluor 488 goat antimouse secondary antibody (1:600 dilutions,
A11029; Invitrogen). All slides were rinsed, incubated with Hoechst
33342 (H3570; Invitrogen) to visualize nuclei, and then mounted with
a glycerol/PBS solution containing 0.1 M propyl gallate to minimize
fluorescent bleaching. All images were captured with an Olympus mi-
croscope (BX-51) with an attached DP71 digital camera and processed
with DP Controller and DP Manager software (Olympus).
Quantification of Proliferating Cells and Apoptotic Cells
To quantify proliferating cells and apoptotic cells, BrdU-positive cells
or TUNEL-positive cells in 10 random 0.159-mm2 fields of the tumors
were counted at 100× magnification as described previously [8].
Radioligand Binding Assay
Radioligand binding assays on cell lines were performed by diluting
cells in Dulbecco modified Eagle medium, 25 mM HEPES, pH 7.4,
and 0.1% bovine serum albumin (Sigma). Cells were then incubated
with 125I-labeled ET-1 in the presence or absence of competing ligands
on ice for 4 hours in a total volume of 250 μl in 96-well microtiter
plates. BQ-123 (10 μM final concentration) (Sigma) and Sarafotoxin
6c (1 μM final concentration; Sigma) were used as competitive ligands
for ETAR- and ETBR-specific binding, respectively. The bound ligand
was separated from free ligand by filtration through GF/C filters pre-
soaked with binding buffer by cell harvester (Filtermate; Packard Bio-
science, Meriden, CT). After the addition of ReadySafe (Beckman,
Fullerton, CA) scintillation fluid, bound radioactivity was quantitated
using the TopCountNXT (Packard).
Radioligand binding assays were performed on tumor sections
by equilibrating slides to room temperature before blocking twice for
10 minutes each in assay buffer (50 mM Tris-HCl, pH 7.5, 5 mM
MgCl2, 5% skimmed milk). Slides were then briefly dipped in distilled
water and dried under a stream of cold air for 2 minutes. Sections were
incubated for 4 hours at room temperature with 100 pM 125I-ET-1
in assay in the presence or absence of competitive ligands. BQ-123
(50 μM final; Sigma) and Sarafotoxin 6c (10 μM final concentration;
Sigma) were used as competitive ligands for ETAR- and ETBR-specific
binding, respectively. After incubation, sections were washed four times
for 2 minutes in ice-cold wash buffer (50 mM Tris-HCl, pH 7.5,
5 mMMgCl2), briefly dipped in distilled water at 4°C, and dried under
a stream of cold air. Sections were exposed to BAS2500 imaging plate
(Fuji Photo Film, Kanazawa, Japan) overnight and then Kodak Biomax
MS film (Rochester, NY) for 2 days.
ET Secretion
ET levels were quantified using the QuantiGlo ET-1 Immuno-
assay (R&D Systems, Abingdon, UK) according to the manufacturer’s
instructions. For quantification of ET produced by cell lines, 50,000
cells were seeded per well of a 24-well plate and ET levels measured
48 hours later.
Statistical Analyses
Tumor incidence, the incidence of ascites (χ 2 test), tumor weight,
ascites volume (Mann-Whitney t test), and the number of BrdU-positive
and the number of TUNEL-positive cells (unpaired Student t test)
were compared across the treatment groups.
Results
ETR and ET Expression in Ovarian Cancer Cell Lines
We first assessed the expression level of ETAR and ETBR and the
level of secreted ETs in two ovarian cancer cell lines, SKOV3ip1 and
IGROV1. In both an ETAR- and an ETBR-specific radioligand assay,
ETBR was not expressed at the cell surface of either cell line (Fig-
ure 1A). In contrast, ETAR was weakly expressed in SKOV3ip1 cells
(ratio of specific to nonspecific binding, 1.8) but absent in IGROV1.
CHO cells overexpressing ETAR or ETBR were used as a positive
control (ratio of specific binding to nonspecific binding, 17 to 22),
and CHO mock-transfected cells were used as a negative control.
Next, we determined the level of ETR expression in SKOV3ip1 tu-
mors growing in the peritoneal cavity of nude mice using ETAR- and
ETBR-specific radioligand assays (Figure 1B). ETAR was highly ex-
pressed in the three tumors (ratio of specific to nonspecific binding,
5.9 to 15.2). ETBR was also expressed in tumors although at a lower
level (ratio of specific to nonspecific binding, 2 to 2.8). The expres-
sion of the ETRs in SKOV3ip1 tumors was also investigated using
immunohistochemistry (Figure 1C ). Both receptors were detected in
the cytoplasm and/or plasma membranes of tumor cells but not in
the nucleus. Consistent with the radioligand assay, both tumor cells
and endothelial cells stained positive for ETAR. In contrast, expres-
sion of ETBR was weak and heterogeneous in tumor cells and more
pronounced in tumor-associated endothelial cells and possibly in in-
filtrating leukocytes [65]. ETAR and ETBR were also found to be
expressed in tumors derived from IGROV1 cells growing in the peri-
toneal cavity of nude mice as determined by immunofluorescence
(data not shown). Collectively, these results indicate that the expres-
sion of ETRs was stronger in ovarian cancer cells growing in vivo
than in vitro.
We next determined the level of ET secretion by the cell lines
growing in vitro. As shown in Figure 1A, SKOV3ip1 and IGROV1
cells expressed levels of ET (35 and 25 pg/ml, respectively) that were
similar to those measured in immorto mouse lung endothelial cells
(26 pg/ml). The level of ET secretion in SKOV3ip1 tumors was de-
termined by measuring the level of ETs in ascitic fluids (Figure 1D).
ETs could be detected in ascites of the three mice tested with levels
ranging from 6.9 to 16 pg/ml.
Therapy for SKOV3ip1 and IGORV1 with Macitentan
and Paclitaxel
In the first set of therapy experiments, treatment of SKOV3ip1
with paclitaxel significantly decreased tumor weight as compared
with the control group (Table 1A; median [range]: 0.4 g [0.1-0.5 g]
vs 1.1 g [0-1.8 g], P < .05). Tumor weight in mice treated with only
macitentan was not reduced. The combination of paclitaxel and
macitentan further decreased tumor weight (0.1 g [0-0.3 g], P <
.01). Treatment with a combination of paclitaxel and macitentan also
significantly decreased tumor incidence as compared with the control
group (5/9 vs 8/10, P < .05). The incidence and volume of ascites
were significantly decreased by the treatment with paclitaxel (4/9 vs
8/10, P < .05; and median [range] of 0.4 ml [0-0.9 ml] vs 0.1 ml
[0-0.2 ml], P < .01, respectively) and the combination therapy com-
pletely inhibited development of ascites (0/9 vs 8/10, P < .01). The
combination of macitentan with paclitaxel significantly enhanced the
therapeutic efficacy of paclitaxel as measured by tumor weight (0.4 g
[0.1-0.5 g] vs 0.1 g [0-0.3 g], P < .01), tumor incidence (9/9 vs 5/9,
P < .05), and incidence of ascites (4/9 vs 0.9, P < .05).
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In a repeated therapy experiment using 50 mg/kg macitentan, sim-
ilar therapeutic effects were found in mice treated with the combi-
nation of paclitaxel and macitentan (data not shown).
In mice bearing IGROV1 tumors in the peritoneal cavity, treat-
ment with paclitaxel significantly decreased tumor weight as com-
pared with control mice (0.5 g [0-0.9 g] vs 1.1 g [0.4-2.1 g], P <
.05; Table 1B). Treatment with macitentan alone did not pro-
duce a significant therapeutic effect. The combination of macitentan
(50 mg/kg) and paclitaxel (5 mg/kg) further decreased the weight of
the tumors (0.3 g [0-0.6 g] vs 1.1 g [0.4-2.1 g], P < .01; Table 1B).
Macitentan combined with paclitaxel significantly enhanced the ther-
apeutic efficacy of paclitaxel as measured by tumor weight (0.5 g
[0-0.9 g] vs 0.3 g [0-0.6 g], P < .05). Mice treated with macitentan
at 100 mg/kg exhibited poor skin turgor, dehydration, diarrhea, and
sluggishness. For this reason, in the next set of experiments, we deter-
mined the biologically optimal dose of macitentan. Treatment with
paclitaxel (5 mg/kg) and 3 or 10 mg/kg macitentan did not produce
enhanced therapeutic effects (data not shown). In contrast, treatment
with 5 mg/kg paclitaxel combined with 30 mg of macitentan signi-
ficantly reduced tumor weight but not tumor incidence (data not
shown). For these reasons, all future experiments used a macitentan
dose of 50 mg/kg administered daily to treat SKOV3ip1 and IGROV.
Figure 1. Expression level of ETAR, ETBR, and secreted ETs by SKOV3ip1 and IGROV1 cells growing in vitro and in vivo. (A) ET secretion
was determined by ELISA in culture supernatant of SKOV3ip1, IGROV1, and mouse lung endothelial cells in vitro 48 hours after seeding.
ETAR and ETBR expression was determined using a radioligand binding method. Nonspecific binding (NSB) was determined by incu-
bating cells with BQ-123 or Sarafotoxin 6c. The ratio binding-B/NSB indicates the specific binding. ETAR and ETBR expression was mea-
sured by radioligand binding (B) and immunohistochemistry (C) in SKOV3ip1 tumors growing in the peritoneal cavity of nude mice
(arrows indicating endothelial cells). (D) ET secretion was measured by ELISA in ascites from three control mice and three mice injected
intraperitoneally with SKOV3ip1 cells and treated with macitentan (50 mg/kg).
Table 1. Treatment of Human Ovarian Cancers SKOV3ip1 (A) and IGROV1 (B) Growing in the
Peritoneal Cavity of Female Nude Mice with Macitentan and Paclitaxel.
(A)
Treatment Group Tumor
Incidence
Tumor Weight,
Median (Range), g
Ascite
Incidence
Ascites, Median
(Range), ml
Control 8/10 1.1 (0-1.8) 8/10 0.4 (0-0.9)
Paclitaxel, 5 mg/kg 9/9 0.4 (0.1-0.5)* 4/9* 0.1 (0-0.2)†
Macitentan, 100 mg/kg 7/10 2.3 (0-4.6) 7/10 0.4 (0-4.7)
Paclitaxel + macitentan 5/9*,‡ 0.1 (0-0.3)†,‡ 0/9†,‡ 0†
(B)
Treatment Group Tumor Incidence Tumor Weight, Median
(Range), g
Control 10/10 1.1 (0.4-2.1)
Paclitaxel, 5 mg/kg 9/10 0.5 (0-0.9)*
Macitentan, 50 mg/kg 10/10 0.7 (0.4-1.3)
Paclitaxel + macitentan 9/9 0.3 (0-0.6)†,‡
Mice were injected intraperitoneally with 1 × 106 SKOV3ip1 or IGROV1 cells. Ten days later,
treatment began with vehicle, paclitaxel, macitentan, or a combination of macitentan and pacli-
taxel. Treatment continued for 4 weeks when mice were examined by necropsy. Tumor incidence,
weight, incidence, and volume of ascites were recorded.
*Statistically significant compared with the control group, P < .05.
†Statistically significant compared with the control group, P < .01.
‡Statistically significant compared with the paclitaxel group, P < .05.
Neoplasia Vol. 13, No. 2, 2011 Blockade of ETR for Therapy of Ovarian Cancer Kim et al. 171
Sensitization or Ovarian Cancer Cells to Paclitaxel
with Macitentan
Mice were implanted with 1 × 106 SKOV3ip1 cells, and 10 days
later when tumors were established, treatment began either with non-
therapeutic (2 mg/kg) or therapeutic (5 mg/kg) doses of paclitaxel
(Table 2). Nontherapeutic doses of paclitaxel (2 mg/kg) did not de-
crease the weight of the tumors (2.5 g [1.2-3.3 g]) compared with
the control group (1.9 g [0.5-4.8 g], P > .05). However, the com-
bination of macitentan (50 mg/kg) with a nontherapeutic dose of
paclitaxel (2 mg/kg) significantly decreased the tumor weight (0.3 g
[0-0.7 g], P < .001) compared with control mice or mice treated with
only a nontherapeutic dose of paclitaxel (2.5 g [1.2-3.3 g], P < .001;
Table 2). Tumor incidence (5/10 vs 10/10) and incidence of ascites
(4/10 vs 10/10) were also significantly decreased (P < .05) implying
that administration of macitentan at 50 mg/kg increases the sensitiv-
ity of tumor cells to paclitaxel. Interestingly, whereas treatment with
100 mg/kg of macitentan as a single agent did not show therapeutic
benefits (Table 1), mice treated with a nontoxic dose of 50 mg/kg
macitentan as a single agent had a decrease in tumor weight (0.6 g
[0-1.1 g] vs 1.9 g [0.5-4.8 g], P < .05). The full therapeutic efficacy
in this study, however, was produced by combining 5 mg/kg paclitaxel
with 50 mg/kg macitentan (0.1 g [0-0.5 g], P < .001).
From these three sets of experiments, we conclude that 50 mg/kg
macitentan administered once a day is the biologic optimal dose, and
less than 10 mg/kg is an ineffective dose in the SKOV3ip1 tumor.
The 50-mg/kg dose of macitentan did not produce toxicity.
Immunohistochemical Analyses of the ET Axis and Signaling
Molecules in SKOV3ip1 and IGROV1
Tumor cells and tumor associated endothelial cells of SKOV3ip1
(Figure 2) and IGROV1 (not shown) peritoneal tumors were ana-
lyzed for expression of ET-1, ET-2, ETAR, and ETBR. Treatment
with paclitaxel (5 mg/kg), macitentan (100 mg/kg), or a combination
of paclitaxel and macitentan did not alter the expression of the li-
gands or the receptors in both tumor cells and tumor-associated en-
dothelial cells (Figure 2, A and B). ET-1, ET-2, ETAR, and ETBR
produced green fluorescence, and endothelial cells (CD31) produced
red fluorescence. Thus, colocalization of ET-1, ET-2, ETAR, or
ETBR with CD31 produced a yellow stain (Figure 2, A and B).
Table 2. Treatment of HumanOvarianCancer, SKOV3ip1, withMacitentan and Paclitaxel Growing
in the Peritoneal Cavity of Female Nude Mice.
Treatment Group Tumor
Incidence
Tumor Weight,
Median (Range), g
Ascite
Incidence
Vehicle 10/10 1.9 (0.5-4.8) 10/10
Paclitaxel, 2 mg/kg 10/10 2.5 (1.2-3.3) 10/10
Paclitaxel, 5 mg/kg 10/10 0.4 (0.2-1.3)* 5/10†
Macitentan, 50 mg/kg 9/10 0.6 (0-1.1)† 7/10
Paclitaxel, 2 mg/kg + macitentan 5/10†,‡ 0.3 (0-0.7)†,§ 4/10†,‡
Paclitaxel, 5 mg/kg + macitentan 5/10†,‡ 0.05 (0-0.5)*,§ 0/10†,‡
Mice were injected intraperitoneally with 1 × 106 SKOV3ip1 cells. Ten days later, treatment with
vehicle, paclitaxel, macitentan, or macitentan and paclitaxel began and continued for 4 weeks. At
the end of the experiments, the mice were examined by necropsy. Tumor incidence, weight, and
incidence and volume of ascites were recorded.
*Statistically significant compared with the control group, P < .01.
†Statistically significant compared with the control group, P < .05.
‡Statistically significant compared with the 2-mg/kg paclitaxel-treated group and 5-mg/kg paclitaxel-
treated group, respectively, P < .05.
§Statistically significant compared with the 2-mg/kg paclitaxel-treated group and 5-mg/kg paclitaxel-
treated group, respectively, P < .01.
Figure 2. Immunohistochemical analyses of human ovarian carcinoma SKOV3ip1 growing in the peritoneal cavity of nude mice treated
with macitentan and paclitaxel. SKOV3ip1 tumor tissues were harvested and processed for the frozen sections. Tissues were stained
with anti-CD31 antibody (red) and anti–ET-1, ET-2, ETAR, or ETBR antibody (green). Expression of ET-1, ET-2, ETAR, or ETBR on tumor-
associated endothelial cells yielded yellow signal by colocalization of red and green. Experimental conditions; see Table 1A. (A) ET-1 and
ET-2 were expressed on tumor cells (green) as well as tumor-associated endothelial cells (yellow) and treatment with ETR antagonist,
macitentan, with or without paclitaxel, did not affect the expression of ET-1 or ET-2. (B) ETAR and ETBR were expressed on tumor cells
(green) as well as tumor-associated endothelial cells (yellow), and treatment with ETR antagonist, macitentan, with or without paclitaxel,
did not affect the expression of ETAR or ETBR.
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The ETreceptor antagonist, macitentan, did not affect the expression
of ET-1, ET-2, ETAR, or ETBR on the tumor cells or tumor-associated
endothelial cells.
Treatment with macitentan alone (50 mg/kg) or treatment with a
combination of macitentan and paclitaxel (5 mg/kg) significantly de-
creased the levels of pVEGFR2, pAkt, and pMAPK in tumor cells
and in tumor-associated ET cells (note decreased yellow signal as
compared with the control group) (IGROV1; Figure 3).
When pVEGFR and pAkt were analyzed in SKOV3ip1 tumors
from mice treated with different doses of macitentan, the 10 mg/kg
administered daily did not inhibit Akt and VEGFR phosphoryla-
tion, whereas the 30 mg/kg administered daily strongly inhibited
Akt phosphorylation and, to a lesser extent, VEGFR phosphorylation.
When macitentan was administered at 100 mg/kg, both pAkt and
pVEGFR were completely inhibited, and this correlated with the
stronger efficacy in terms of tumor incidence (data not shown).
Because β-arrestin is recruited to the ETRs [48] via binding to
serine/threonine phosphorylated sites at the cytoplasmic C-terminus
of the receptor proteins, we applied double immunofluorescence
staining for phosphorylated serine and ETRs to tumor tissues to
Figure 2. (continued).
Figure 3. Immunohistochemical analyses of IGROV1 growing in the peritoneal cavity of nude mice treated with macitentan and pacli-
taxel. IGROV1 tumor tissues were harvested and processed for the frozen section. Tissues were stained with anti-CD31 antibody (red)
and anti-pVEGFR2, pAkt, or pMAPK antibody (green). Expression of pVEGFR2, pAkt, or pMAPK on tumor-associated endothelial cells
yielded a yellow signal by colocalization of red and green. Treatment with macitentan significantly decreased the expression of
pVEGFR2, pAkt, and pMAPK on tumor cells as well as tumor-associated endothelial cells (arrows). Treatment with paclitaxel did not
show a significant change in expression of pVEGFR2, pAkt, or pMAPK. Experimental conditions; see Table 1B.
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probe the activation status of the receptors by assessing colocalization
of antibody binding.
Phosphorylated serine was captured as green, and ETAR and
ETBR were captured as red. Colocalization of phosphorylated serine
and ETAR or ETBR (phosphorylated ETRs) yielded yellow. Colocali-
zation was significantly decreased in a dose-dependent manner (Fig-
ure W3). Treatment of mice with 50 mg/kg macitentan significantly
inhibited colocalization (yellow) of phospho-serine (green) and of
ETAR or ETBR (red), indicating inhibition of ETR phosphorylation.
The nuclei were stained with Hoechst 33342 (blue) (Figure 4).
Proliferation and Apoptosis of Cells in Tumors
Treatment of SKOV3 tumors with paclitaxel alone at 5 mg/kg sig-
nificantly decreased the number of BrdU-positive proliferating cells
(green tumor cells and yellow endothelial cells) and increased the num-
ber of apoptotic tumor cells (TUNEL-positive, green) and TUNEL-
positive endothelial cells (TUNEL-positive, yellow) (SKOV3ip1;
Table 3A and Figure 5). Treatment with macitentan (50 or 100 mg/kg)
alone also increased the number of apoptotic tumor cells and endo-
thelial cells but did not decrease the number of proliferating tumor
cells (Figure 5). Combination therapy with macitentan and paclitaxel
significantly increased the number of apoptotic tumor cells compared
with paclitaxel or macitentan alone. Furthermore, the combination
therapy also increased apoptosis in tumor-associated endothelial cells
(Figure 5). Proliferating and apoptotic cells were quantified by count-
ing BrdU-positive cells and TUNEL-positive cells, respectively, in
10 random 0.159-mm2 fields at 100× magnification (Table 3). In
SKOV3ip1 tumors, paclitaxel (5 mg/kg) significantly increased the
number of TUNEL-positive cells compared with control treatment.
Treatment with macitentan (50 mg/kg) also significantly increased
the number of apoptotic cells. The combination of paclitaxel and
macitentan yielded the highest level of apoptosis (with statistical sig-
nificance compared with the paclitaxel group [195.3 ± 42.6 vs 150.0 ±
38.3], P < .01). The number of proliferating cells was significantly
decreased by treatment with paclitaxel; however, treatment with
macitentan alone did not significantly decrease the number of pro-
liferating cells. The combination of paclitaxel and macitentan further
decreased the number of proliferating cells, but it was not statistically
significant compared with tumors treated with only paclitaxel (18.5 ±
11.1 vs 30.8 ± 14.9, P < .051; Table 3A).
In IGROV1 tumors (Table 3B), treatment with paclitaxel (5 mg/kg)
significantly increased the number of apoptotic cells, and treatment
with macitentan (50 mg/kg) alone also significantly increased the
apoptotic cells (69 ± 13.1 vs 5.7 ± 3.3, P < .05) compared with the
control group. The combination of paclitaxel and macitentan yielded
the best outcome compared with paclitaxel-treated mice (181.4 ±
32.9 vs 139.0 ± 29.7, P < .05). The number of proliferating cells
was significantly decreased by the treatment with paclitaxel compared
with the control group. Treatment with macitentan alone did not in-
duce a significant decrease in the number of proliferating cells. Treat-
ment with both paclitaxel and macitentan further decreased cell
proliferation as compared with the paclitaxel group, but the decrease
was not statistically significant (19.3 ± 8.8 vs 28.2 ± 10.0, P = .057;
Table 3B).
In the third set of experiments, treatment with the nontherapeutic
dose (2 mg/kg) of paclitaxel did not induce significant apoptosis of
tumor cells (green) or tumor-associated endothelial cells (yellow),
but the combination of macitentan (50 mg/kg) with 2 mg/kg pacli-
taxel induced significant apoptosis in both the tumor cells and tumor-
associated endothelial cells (Figure 6). The number of apoptotic cells
Figure 4. Double immunofluorescence staining for phosphorylated
ETRs. The SKOV3ip1 tumors in control mice and paclitaxel-treated
mice expressed phosphorylated ETAR and ETBR (yellow color
derived from dual colocalization of red anti-ETR, and green anti–
phospho-serine). Treatment with macitentan alone (50 mg/kg once
a day) or macitentan plus paclitaxel (5 gm/kg once a week) sup-
pressed phosphorylation of the ETRs (red signal equal to nonphos-
phorylated receptors). Size of tumor cells is variable, depending on
the harvest site.
Table 3. Quantitative Analysis of Dividing and Apoptotic Cells in Human Ovarian Cancers
SKOV3ip1 (A) and IGROV1 (B) Growing in the Peritoneal Cavity of Nude Mice.
Treatment Group BrdU* TUNEL*
(A)
Control 64.8 ± 20.0 6.5 ± 3.2
Paclitaxel, 5 mg/kg 30.8 ± 14.9† 150.0 ± 38.3†
Macitentan, 50 mg/kg 48.7 ± 15.1 54.7 ± 17.9†
Paclitaxel + macitentan 18.5 ± 11.1† 195.3 ± 42.6†,‡
(B)
Control 55.2 ± 13.9 5.7 ± 3.3
Paclitaxel, 5 mg/kg 28.2 ± 10.0‡ 139.0 ± 29.7†
Macitentan, 50 mg/kg 45.9 ± 13.4 69.0 ± 13.1†
Paclitaxel + macitentan 19.6 ± 8.8† 181.4 ± 32.9†,‡
*Number of cells in 0.159-mm2 field.
†Statistically significant compared with the control group (P < .05).
‡Statistically significant compared with the paclitaxel group (P < .01).
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induced by the therapeutic dose of paclitaxel (5 mg/kg) was increased
by combining the paclitaxel with macitentan (Figure 6).
Discussion
The purpose of the present study was to determine whether blockade
of ETRs by macitentan, coupled with administration of paclitaxel,
decreases the progressive growth of human ovarian cancer cells im-
planted into the peritoneal cavity of nude mice and to identify po-
tential pharmacodynamic markers, which could be useful in dose
finding and therapy. Multiple studies indicate that ET and ETRs
contribute to the progressive growth of ovarian cancer [25,39–48]
and expression of the ETAR has been shown to correlate with ad-
vanced stages of ovarian cancer in patients [39,66,67]. Gene expres-
sion profiles of advanced ovarian cancer further indicate that ETAR
expression is associated with cell migration and invasion [66,67].
ET-1 has also been shown to promote survival of cells through Bcl-
2–dependent mechanisms and inhibit paclitaxel-mediated apoptosis
[39]. In the current study, we demonstrated, using two ovarian cancer
cell lines grown in vitro and in vivo, that ETRs were preferentially
expressed when tumors were grown in vivo. Both tumors produced
ET in vitro and in vivo in ascites (SKOV3ip1). Immunohistochemistry
confirmed the expression of ETRs on tumor cells (ETAR) and on
tumor-associated vascular endothelial cells (ETBR). As demonstrated
in therapy experiments, inhibition of ET signaling sensitized not only
tumor cells but also tumor-associated endothelial cells to killing
by paclitaxel.
Results obtained in preclinical cancer models [49,68] and in ana-
lyzing clinical tumor specimens led to clinical studies of ETR antago-
nists, mainly using ETAR-selective antagonists in hormone-refractory
and metastatic prostate cancer [49,69,70]. Clinical data obtained
with ETAR selective antagonists in prostate cancer patients, in partic-
ular with zibotentan, justify additional studies of these antagonists,
both in prostate cancer and in other tumors [70,71]. The dual recep-
tor antagonist, bosentan, has been studied in melanoma patients in a
phase 2 trial [72] based on data that indicate a fundamental role of
the ETBR in melanocyte physiology [73] and a correlation of ETBR
overexpression in melanoma with tumor progression [74]. The single
agent phase 2 study suggested that additional studies of the agent in
combination with other anticancer drugs were warranted.
A double-blind, placebo-controlled study of high-dose bosentan,
in combination with dacarbazine, was performed in patients with
stage IV metastatic melanoma. In this study, the addition of bosentan
had no effect on time to tumor progression or other measures of
efficacy [75]. No pharmacodynamic markers were applied to deter-
mine the drug action in tumors. The inability of this drug to affect
response to dacarbazine may be due to poor tissue penetration by
bosentan because ET and ETRs are expressed in cancer cells and tu-
mor stroma. Macitentan was selected for our study because of its
high tissue targeting properties and for targeting both the ETARs
and ETBRs [61].
In pathologic situations, both ETA and ETB receptors have been
shown to mediate vasoconstriction [76], smooth muscle proliferation
[77], and inflammation [78]. These findings, together with those we
describe regarding the highly expressed ET axis in tumors, make fur-
ther evaluation of dual ETreceptor antagonists in oncology warranted.
The efficacy of ETAR-selective inhibitors have been tested in ovar-
ian cancer xenografts. ABT-627 (atrasentan) has shown antitumor
efficacy in subcutaneously transplanted HEY ovarian tumors alone
Figure 5. Cell proliferation and apoptosis in control and macitentan-treated SKOV3ip1 tumors growing in the peritoneal cavity of nude
mice. SKOV3ip1 tumor tissues were harvested and processed for the frozen section. To detect proliferating or apoptotic cells, tissues
were stained with anti-CD31 antibody (red) and anti-BrdU antibody or TUNEL staining (green), respectively. Colocalization of BrdU-
or TUNEL-positive cells with CD31 yielded yellow signals. Treatment with paclitaxel significantly decreased the number of proliferat-
ing cells (BrdU-positive cells) but macitentan alone did not significantly decrease the number of BrdU-positive cells. Combination of
macitentan and paclitaxel did not induce significant additive effects over the effects of paclitaxel on proliferating cells. Treatment with
macitentan alone significantly increased the number of apoptotic cells (TUNEL-positive), and the combination treatment significantly
enhanced the effects of paclitaxel on tumor cells and associated endothelial cells (yellow). Experimental conditions; see Table 1A.
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and in combination with Taxol. The antitumor effect was accom-
panied with reduced production of VEGF, reduced expression of
matrix metalloproteinase 2, and an increase in the number of apop-
totic tumor cells [79]. In other studies using the HEY tumor model,
ABT-627 efficacy was confirmed, and in one case, the antitumor
effect was associated with the reversal of markers typical for the
epithelial-to-mesenchymal transition [80] and in another case with
the reduction of integrin-linked kinase expression and reduced
AKT and GSK-3β phosphorylation [81]. The ETAR selective antag-
onist ZD4054 (zibotentan) showed antitumor activity in subcu-
taneous HEY ovarian tumor xenografts alone and in combination
with paclitaxel [65] and the epidermal growth factor receptor kinase
inhibitor gefitinib [40]. Administration of ZD4054 reduced VEGF
expression and phosphorylation of p42/44 MAP kinase and inhibited
growth of metastatic nodules after intraperitoneal transplantation of
HEY ovarian cancer cells [48]. In this case, the metastatic phenotype
was linked to ETAR-mediated β-arrestin signaling and activation of
the wnt pathway.
In the present study, we show that blockade of the ET axis by the
dual ETR antagonist macitentan inhibits the growth of human ovar-
ian cancer cells, SKOV3ip1 and IGROV1, in the peritoneal cavity of
nude mice (orthotopic site). SKOV3ip1 and IGROV1 cells were
both sensitive to paclitaxel and highly express ETRs in vivo. The
SKOV3ip1 tumor also produces ET in ascites fluid. Treatment with
macitentan as a single agent did not produce significant therapeutic
effects, but combining paclitaxel with macitentan did. The blockage
of the ETBR was demonstrated by the increased level of ET in ascites
in the macitentan groups (Figure 1D). Immunohistochemical analy-
ses demonstrated that, although treatment with macitentan did not
change the expression levels of ET-1, ET-2, ETAR, and ETBR in tu-
mor cells, it significantly decreased the phosphorylation of ETRs and
such cell survival pathway markers as pVEGFR2, pAkt, and pMAPK
Figure 6. Induction of apoptosis in SKOV3ip1 tumors by paclitaxel and macitentan. SKOV3ip1 tumor tissues were harvested and pro-
cessed for frozen section. Tissues were stained with CD31 and TUNEL to detect the apoptotic cells. Treatment with nontherapeutic
dose (2 mg/kg) of paclitaxel did not induce apoptosis of tumor cells or tumor-associated endothelial cells, but its combination with
macitentan made cells sensitive to this low dose of paclitaxel, which was clearly demonstrated by induction of significant apoptosis
of tumor cells as well as tumor-associated endothelial cells (arrows). Macitentan significantly further enhanced the effect of the ther-
apeutic dose (5 mg/kg) of paclitaxel. Experimental conditions; see Table 2.
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[59,82,83]. These data extend those in earlier reports [39,40,79,81].
Treatment with macitentan alone increased the number of apoptotic
cells, and its combination with paclitaxel significantly enhanced
apoptosis in tumor cells and the tumor-associated endothelial cells
compared to each agent alone, indicating loss of blood vessels. Sim-
ilarly, paclitaxel and the drug combination significantly decreased
the number of proliferating cells, whereas macitentan alone did
not. Collectively, these results suggest that blockade of the ET axis
may suppress antiapoptotic mechanisms in tumor cells and associated
endothelial cells by affecting survival pathways through the inhibi-
tion of phosphorylation of pAkt, pMAPK, and pVEGFR2. Thus,
treatment with macitentan rendered tumor cells and tumor-associated
endothelial cells more sensitive to paclitaxel, even when paclitaxel was
administered at the dose of 2 mg/kg, which is less than half of its ther-
apeutic dose (5 mg/kg). This suggests that the combination of the ET
antagonist macitentan with a suboptimal dose of the chemotherapeutic
agent may be just as effective as paclitaxel alone at the higher thera-
peutic dose.
The efficacy of macitentan was correlated with inhibition of pro-
tein phosphorylation in a dose-response study. Doses of macitentan
that did not increase the efficacy of paclitaxel did not downregulate
expression of pAkt, pMAPK, or pVEGFR. These markers can there-
fore be used as pharmacodynamic biomarkers to determine the min-
imal effective dose in other animal models or patients. Importantly, a
direct measurement of the activation state of the ETRs would be a
most desirable biomarker. It has recently been shown that ETRs also
signal through the β-arrestin pathway [48]. β-Arrestin binding to an
activated G protein–coupled receptor requires phosphorylation of the
C-terminal intracellular part of the receptor at the amino acids serine
or threonine by G protein–coupled receptor kinases [84]. Because
antibodies that are able to detect phospho-serine or phospho-threonine
in an ETR-specific peptide sequence are not available, we determined
the phosphorylation of ETRs by colocalization of ETRs and phosphor-
ylated serine using anti-ETR and nonspecific anti–phospho-serine
antibodies. Colocalized signals of ETRs and phosphorylated serine
were decreased in a dose-dependent manner in tumors of animals
treated with efficacious doses of macitentan, indicating blockage of
ETR activation by the receptor antagonist. This colocalization assay
is highly dependent on the specificity of the antibodies. To increase
the link of this assay with the activation status of ETR, in vitro cell
culture experiments with SKOV3ip1 cells were performed. In these
experiments, concentrations as low as 100 nM macitentan, which
has been shown to functionally inhibit ETR signaling in cellular assays
[61], were able to block ET-1–induced colocalization of the antibodies
(data not shown). Preliminary determination of macitentan level in the
plasma correlated with the localization of ETR-pSer in the tumors.
These measurements may therefore serve as biomarkers most closely
linked to ETR activation.
Our present study clearly demonstrates that treatment of mice
with macitentan and paclitaxel inhibited phosphorylation of ETRs
in tumor cells and tumor-associated vascular endothelial cells and
produced apoptosis in both cell types. Previous data from our labo-
ratory demonstrated that therapy for ovarian cancer [62], colon can-
cer [85], and prostate cancer [86,87] can be mediated by targeting
the tumor vasculature.
In summary, this study confirms the efficacy of inhibiting cell sig-
naling pathways and tumor growth by ETR antagonists in combi-
nation with paclitaxel in orthotopic models of ovarian cancer. Of
importance, macitentan decreased the effective dose of paclitaxel. Ef-
ficacy is associated not only with tumor cell killing but also with
destruction of tumor-associated vascular endothelial cells. The con-
tribution to paclitaxel efficacy of the tissue-targeting dual ETR antag-
onist macitentan was correlated with inhibition of phosphorylation
of signaling and survival proteins. Therefore, the degree of protein
phosphorylation might be used as a pharmacodynamic biomarker
in future studies and supports the finding of the biologically active
therapeutic dose.
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Figure W1. SKOV3ip1 growing in the peritoneal cavity of nudemice.
Ten days after the intraperitoneal injection of 1 × 106 SKOV3ip1
cells, three mice were randomly selected and necropsied. Tumor
burden was documented before the start of treatment.
Figure W2. Necropsy procedure. At the end of the experiment, mice were necropsied. Peritoneal tumors were collected and weighed.
(A) Control group of SKOV3ip1. (B) Control group of IGROV1. Range of the tumor size was within the normal distribution curve. *One
mouse in the IGROV1 control group became moribund and was killed 1 day before the completion of the experiment.
Figure W3. Colocalization of pSer with ETAR (A) and ETBR (B). Immunofluorescence analyses were performed in SKOV3ip1 tumors
growing in the peritoneal cavity of nude mice. Phosphorylated serine signal was coded green, and receptors were coded red. Coloca-
lizations yield yellow signals. Phosphorylation of endothelin receptors was inhibited by ACT-064992 in a dose-dependent manner. Endothelin
receptors A and Bwere phosphorylated in tumors treated with vehicle, paclitaxel, and paclitaxel combined with 3 or 10 mg/kg ACT-064992. In
contrast, phosphorylation of endothelin receptors A and B was significantly inhibited in tumors treated with paclitaxel combined with 30 or
50 mg/kg ACT-064992.
